Clinical Trial Update: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating tuvusertib in combination with cemiplimab for non-small cell lung cancer is currently active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cemiplimab (cemiplimab)
• Tuvusertib (tuvusertib)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING